NCT02484677View on ClinicalTrials.gov

Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

January 25, 2017

Study Completion Date

May 25, 2023

Conditions

Patients With Head and Neck Cancer (ORL)

Interventions

DRUG

Cisplatin

Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation

DRUG

Docetaxel

Taxanes. Blood sampling for pharmacokinetic evaluation

DRUG

5-Fluorouracile

Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation

Trial Locations (1)

13354

Assistance Publique Hôpitaux de Marseille, Marseille

All Listed Sponsors

lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT02484677 - Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy | Biotech Hunter | Biotech Hunter